Ameriprise Financial Inc Alnylam Pharmaceuticals, Inc. Transaction History

Ameriprise Financial Inc

$381 Billion
Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 137,838 shares of ALNY stock, worth $32.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

137,838

Previous 238,320 42.16%

Holding current value

$32.3 Million

Previous $57.9 Million 34.53%

% of portfolio

0.01%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$233.81 - $287.01 $23.5 Million - $28.8 Million	-100,482 Reduced 42.16%	137,838 $37.9 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $6.25 Million - $10.8 Million	43,595 Added 22.39%	238,320 $57.9 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $26.8 Million - $36.3 Million	-182,934 Reduced 48.44%	194,725 $29.1 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $49.7 Million - $64.6 Million	-328,541 Reduced 46.52%	377,659 $72.3 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $13.8 Million - $17.1 Million	80,862 Added 12.93%	706,200 $125 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $78.1 Million - $89.5 Million	422,168 Added 207.79%	625,338 $119 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $28.5 Million - $36.7 Million	155,795 Added 328.85%	203,170 $40.7 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $7.01 Million - $9.12 Million	37,804 Added 394.98%	47,375 $11.3 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $126,625 - $212,048	-914 Reduced 8.72%	9,571 $1.91 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $260,950 - $366,851	-2,167 Reduced 17.13%	10,485 $1.54 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $14,625 - $19,999	115 Added 0.92%	12,652 $2.02 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $290,877 - $381,535	1,823 Added 17.02%	12,537 $2.07 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $7.8 Million - $9.54 Million	-45,941 Reduced 81.09%	10,714 $2.02 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $935,654 - $1.29 Million	7,274 Added 14.73%	56,655 $9.61 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $968,473 - $1.34 Million	7,636 Added 18.29%	49,381 $7.03 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $1.74 Million - $2.08 Million	14,176 Added 51.42%	41,745 $5.43 Million
Q3 2020 Nov 16, 2020	BUY	$121.19 - $165.49 $304,671 - $416,041	2,514 Added 10.03%	27,569 $4.02 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $1.18 Million - $1.77 Million	11,308 Added 82.26%	25,055 $3.71 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $72,726 - $104,646	781 Added 6.02%	13,747 $1.5 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $3,427 - $5,714	46 Added 0.36%	12,966 $1.49 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $55,940 - $69,289	789 Added 6.5%	12,920 $1.04 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $1.19 Million - $1.67 Million	-18,006 Reduced 59.75%	12,131 $880,000
Q1 2019 May 15, 2019	BUY	$72.76 - $93.45 $19,936 - $25,605	274 Added 0.92%	30,137 $2.82 Million
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $1.7 Million - $2.4 Million	-27,186 Reduced 47.65%	29,863 $2.17 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $4.13 Million - $5.79 Million	-47,219 Reduced 45.29%	57,049 $4.99 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $7 Million - $8.55 Million	79,311 Added 317.79%	104,268 $10.3 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $2.59 Million - $3.32 Million	22,357 Added 859.88%	24,957 $2.97 Million
Q4 2017 Feb 12, 2018	BUY	$114.49 - $139.98 $49,001 - $59,911	428 Added 19.71%	2,600 $331,000
Q3 2017 Nov 07, 2017	BUY	$72.53 - $118.27 $157,535 - $256,882	2,172	2,172 $255,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Alnylam Pharmaceuticals, Inc. Transaction History